X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
Other Certificates
Other Suppliers
0
0
USA (Orange Book)
0
Europe
Canada
0
Australia
0
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
Details:
NPM-115 (exenatide implant) is a GLP-1R (Glucagon-like peptide 1 receptor) agonists, peptide drug, which is being evaluated for the chronic weight management in obesity patients.
Lead Product(s): Exenatide
Therapeutic Area: Nutrition and Weight Loss Product Name: NPM-115
Highest Development Status: PreclinicalProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 28, 2024
Details:
NLY01 is a proprietary long-acting analogue of exendin-4, a glucagon-like peptide-1 receptor (GLP-1R) agonist that slows progression in animal models of parkinson’s and alzheimer’s disease.
Lead Product(s): Exenatide
Therapeutic Area: Neurology Product Name: NLY01
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 27, 2023
Details:
Upon completion of the merger, the Company has to advance the development of Vivani’s portfolio, which includes lead asset NPM-119 (exenatide implant), into clinical-stage development for the treatment of patients with Type 2 diabetes.
Lead Product(s): Exenatide
Therapeutic Area: Endocrinology Product Name: NPM-119
Highest Development Status: PreclinicalProduct Type: Peptide
Partner/Sponsor/Collaborator: Second Sight Medical Products
Deal Size: Undisclosed Upfront Cash: $55.0 million
Deal Type: Merger August 30, 2022
Details:
Nano Precision Medical, leveraging its proprietary NanoPortalTM drug implant technology, is creating a portfolio of new drugs including NPM’s lead program, NPM-119, that address medication non-adherence, a leading reason for poor clinical outcomes.
Lead Product(s): Exenatide
Therapeutic Area: Endocrinology Product Name: NPM-119
Highest Development Status: PreclinicalProduct Type: Peptide
Partner/Sponsor/Collaborator: Nano Precision Medical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger February 07, 2022
Details:
BYDUREON BCise brings an important new therapeutic option to physicians caring for children with this chronic disease that can lead to serious long-term issues if not adequately treated.
Lead Product(s): Exenatide
Therapeutic Area: Endocrinology Product Name: Bydureon
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 23, 2021
Details:
Data at week 24 also showed that exenatide once weekly was generally well tolerated and consistent with the existing safety profile in adults. Phase III trial met primary endpoint, significantly reducing blood sugar (HbA1c) versus placebo.
Lead Product(s): Exenatide
Therapeutic Area: Endocrinology Product Name: Bydureon
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 25, 2021
Details:
Three patent families have been filed to cover novel hormonal combinations: pramlintide-exenatide and glucagon-exenatide-both combinations demonstrated promising effects in obesity treatment.
Lead Product(s): Pramlintide,Exenatide
Therapeutic Area: Nutrition and Weight Loss Product Name: PramExe
Highest Development Status: PreclinicalProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2021
Details:
The Company intends to use the net proceeds of the offering for its anticipated Phase 3 clinical trial in ORMD-0801 and for other clinical trials and R&D activities.
Lead Product(s): Exenatide
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: National Securities Corporation
Deal Size: $21.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 27, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
